NDC product
Guaifenesin and Codeine Phosphate
NDC 0121-1775 · PAI Holdings, LLC
Key facts
| Product NDC | 0121-1775 |
|---|---|
| Proprietary name | Guaifenesin and Codeine Phosphate |
| Nonproprietary name | Guaifenesin and Codeine Phosphate |
| Substances | GUAIFENESIN, CODEINE PHOSPHATE |
| Dosage form | SOLUTION |
| Route | ORAL |
| Labeler | PAI Holdings, LLC |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| DEA schedule | CV |
| Pharmacologic classes | Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Full Opioid Agonists [MoA], Increased Respiratory Secretions [PE], Opioid Agonist [EPC] |
| Marketing start | Oct 1, 2006 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: